Drug Profile

IPED 2015

Alternative Names: IPED2015

Latest Information Update: 12 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Initiator Pharma
Developer Initiator Pharma; MAC Clinical Research
Class Erectile dysfunction therapies; Small molecules
Mechanism of Action Neurotransmitter uptake inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Erectile dysfunction

Most Recent Events

07 Oct 2022 IPED 2015 is still in phase II development for Erectile dysfunction in United Kingdom (Initiator pharma pipeline)
04 Aug 2021 Initiator Pharma plans a phase II trial for Erectile Dysfunction (NCT04969666)
15 Mar 2020 Final efficacy and adverse events data from a phase IIa trial in severe erectile dysfunction released by Initiator pharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com